Sentiment-Signal
15,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | KalVista Pharmaceuticals, Inc. |
|---|---|
| Ticker | KALV |
| CIK | 0001348911 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,37 Mrd. USD |
| Beta | -0,40 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-09-30 | 10-Q | 13,700,000 | -49,482,000 | -0.92 | 339,931,000 | 16,999,000 |
| 2025-07-31 | 10-Q | 1,400,000 | -60,096,000 | -1.12 | 215,505,000 | 40,790,000 |
| 2025-06-30 | 10-Q | -57,596,000 | 59,445,000 | |||
| 2025-04-30 | 10-K | -183,444,000 | -3.69 | 250,770,000 | 95,391,000 | |
| 2025-03-31 | 10-Q | -51,836,000 | 116,758,000 | |||
| 2025-01-31 | 10-Q | -48,509,000 | -0.92 | 275,993,000 | 145,126,000 | |
| 2024-11-30 | 10-Q | 50,000,000 | ||||
| 2024-10-31 | 10-Q | -42,268,000 | -0.91 | 160,831,000 | 133,992,000 | |
| 2024-09-30 | 10-Q | 0 | -39,084,000 | -0.84 | 148,530,000 | |
| 2024-07-31 | 10-Q | 0 | -40,443,000 | -0.87 | 200,198,000 | 172,799,000 |
| 2024-06-30 | 10-Q | -40,340,000 | 180,927,000 | |||
| 2024-04-30 | 10-K | 50,000,000 | -126,644,000 | -3.44 | 235,404,000 | 206,582,000 |
| 2024-04-30 | 10-Q | 50,000,000 | 235,404,000 | 206,582,000 | ||
| 2024-03-31 | 10-Q | -43,105,000 | 217,602,000 | |||
| 2024-01-31 | 10-Q | -29,028,000 | -0.84 | 113,968,000 | 88,583,000 | |
| 2023-10-31 | 10-Q | -27,650,000 | -0.80 | 138,743,000 | 114,446,000 | |
| 2023-07-31 | 10-Q | -25,317,000 | -0.74 | 160,332,000 | 139,335,000 | |
| 2023-04-30 | 10-K | -92,907,000 | -3.33 | 183,202,000 | 161,025,000 | |
| 2023-01-31 | 10-Q | -21,303,000 | -0.75 | 203,468,000 | 184,441,000 | |
| 2022-10-31 | 10-Q | -22,257,000 | -0.90 | 162,838,000 | 143,813,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,686 | 20.22 | -54,300.98 | -71,3% | |
| 2026-04-17 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -1,862 | 20.22 | -37,642.75 | -49,4% | |
| 2026-04-17 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -9,550 | 20.22 | -193,065.67 | -253,5% | |
| 2026-04-17 | Piekos Brian | Officer, Chief Financial Officer | Open Market Sale | -1,862 | 20.22 | -37,642.75 | -49,4% | |
| 2026-03-09 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -6,693 | 16.08 | -107,632.81 | -141,3% | |
| 2026-02-23 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -4,347 | 15.57 | -67,668.88 | -88,8% | |
| 2026-02-23 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -10,034 | 15.57 | -156,197.27 | -205,1% | |
| 2026-02-23 | Piekos Brian | Officer, Chief Financial Officer | Open Market Sale | -1,767 | 15.57 | -27,506.54 | -36,1% | |
| 2026-02-23 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,354 | 15.57 | -83,344.65 | -109,4% | |
| 2026-02-23 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -3,975 | 15.57 | -61,878.03 | -81,2% | |
| 2026-02-18 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -1,038 | 15.00 | -15,570.00 | -20,4% | |
| 2026-02-18 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,163 | 15.00 | -17,445.00 | -22,9% | |
| 2026-02-18 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -1,109 | 15.00 | -16,635.00 | -21,8% | |
| 2026-02-12 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3,354 | 15.70 | -52,657.80 | -69,1% | |
| 2025-12-08 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7,294 | 16.51 | -120,423.94 | -158,1% | |
| 2025-11-24 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -4,331 | 13.45 | -58,256.28 | -76,5% | |
| 2025-11-24 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,296 | 13.45 | -71,236.50 | -93,5% | |
| 2025-11-24 | Piekos Brian | Officer, Chief Financial Officer | Open Market Sale | -4,471 | 13.45 | -60,139.42 | -79,0% | |
| 2025-11-24 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -10,940 | 13.45 | -147,153.94 | -193,2% | |
| 2025-11-24 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -3,813 | 13.45 | -51,288.66 | -67,3% | |
| 2025-11-18 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -2,683 | 14.48 | -38,848.23 | -51,0% | |
| 2025-11-18 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -3,075 | 14.48 | -44,524.46 | -58,5% | |
| 2025-11-18 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -4,466 | 14.48 | -64,665.00 | -84,9% | |
| 2025-11-12 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3,328 | 11.55 | -38,438.40 | -50,5% | |
| 2025-09-08 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7,294 | 15.84 | -115,536.96 | -151,7% | |
| 2025-08-25 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,336 | 13.42 | -31,349.12 | -41,2% | |
| 2025-08-25 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -1,480 | 13.42 | -19,861.60 | -26,1% | |
| 2025-08-22 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,942 | 13.22 | -38,901.48 | -51,1% | |
| 2025-08-22 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -1,864 | 13.22 | -24,647.30 | -32,4% | |
| 2025-08-22 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -10,940 | 13.22 | -144,657.43 | -189,9% | |
| 2025-08-18 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,939 | 13.19 | -38,756.59 | -50,9% | |
| 2025-08-18 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -4,409 | 13.19 | -58,141.48 | -76,3% | |
| 2025-07-09 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -32,979 | 15.69 | -517,522.96 | -679,5% | |
| 2025-06-09 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7,169 | 14.50 | -103,950.50 | -136,5% | |
| 2025-05-23 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,146 | 11.31 | -24,271.69 | -31,9% | |
| 2025-05-22 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -9,999 | 11.88 | -118,743.12 | -155,9% | |
| 2025-05-22 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,689 | 11.88 | -31,933.22 | -41,9% | |
| 2025-05-19 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,776 | 11.84 | -32,875.61 | -43,2% | |
| 2025-05-19 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3,808 | 11.84 | -45,097.38 | -59,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.